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Abstract
Muscular manifestation of myotonic dystrophy type 1 (DM1), a common inheritable degenerative multisystem disorder, is
mainly caused by expression of RNA from a (CTG·CAG)n-expanded DM1 locus. Here, we report on comparative proﬁling of
expression of normal and expanded endogenous or transgenic transcripts in skeletal muscle cells and biopsies from DM1
mousemodels and patients in order to help us in understanding the role of this RNA-mediated toxicity. In tissue ofHSALRmice,
the most intensely used ‘muscle-only’model in the DM1 ﬁeld, RNA from the α-actin (CTG)250 transgene was at least 1000-fold
more abundant than that from the Dmpk gene, or the DMPK gene in humans. Conversely, the DMPK transgene in another line,
DM500/DMSXL mice, was expressed ∼10-fold lower than the endogenous gene. Temporal regulation of expanded RNA
expression differedbetweenmodels. Onset of expressionoccurred remarkably late inHSALRmyoblasts during in vitromyogenesis
whereas Dmpk or DMPK (trans)genes were expressed throughout proliferation and differentiation phases. Importantly,
quantiﬁcation of absolute transcript numbers revealed that normal and expandedDmpk/DMPK transcripts inmousemodels and
DM1 patients are low-abundance RNA species. Northern blotting, reverse transcriptase–quantitative polymerase chain reaction,
RNA-sequencing and ﬂuorescent in situhybridization analyses showed that theyoccur at an absolute number between one and a
few dozen molecules per cell. Our ﬁndings reﬁne the current RNA dominance theory for DM1 pathophysiology, as anomalous
factor binding to expanded transcripts and formation of soluble or insoluble ribonucleoprotein aggregates must be nucleated by
only few expanded DMPK transcripts and therefore be a small numbers game.
Introduction
Myotonic dystrophy type 1 (DM1, OMIM no. 160900) is an auto-
somal dominant repeat expansion disorder, affecting skeletal
and smooth muscle as well as the heart, the endocrine system,
the eye and the central nervous system (1). The multisystemic
manifestation and progression of DM1 are caused by expansion
of a (CTG·CAG)n repeat, located in the 3′-untranslated region
(3′ UTR) of the dystrophia myotonica protein kinase (DMPK) gene
(2) and in an overlapping antisense transcription unit in the DM1
locus (3). In DM1 families the expanded repeat is unstable, both
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somatically and intergenerationally, with a bias toward expan-
sion, causing progression of disease symptoms during ageing
and over successive generations (4).
Several mechanisms may contribute to the molecular patho-
genesis of DM1 (5). ExpandedDMPK transcripts are retained in the
nucleus, where they form focal complexes in insoluble or diffuse-
soluble state by abnormal association with transcription factors
and RNA-binding proteins, like members of the muscleblind-
like family (MBNL1–3), DEAD-box helicases and hnRNP proteins
(1,6,7). In turn, abnormal phase transitions in RNP complexes
lead to sequestering of factors needed for processing of other
transcripts with in trans consequences for faithful alternative
splicing and polyadenylation and expression of miRNAs (7,8).
Production of proteins by ribosomes that decode the normally
untranslated (CUG)n repeat tract in DMPK mRNA by a newly dis-
covered process, coined repeat-associated non-ATG (RAN) trans-
lation, is also possible (9,10). Similar toxic events may occur with
antisense transcripts originating from the complementary
strand of the DM1 locus, overlapping the 3′ end of the DMPK
gene. Abnormal RNAs are thus formed with an expanded
(CAG)n repeat, potentially leading to the production of homopoly-
meric peptides by RAN translation of the (CAG)n repeat, which
may evoke an imbalance in proteostasis (9,10). Finally, it cannot
be excluded that problemswithDNA replication across the repeat
tract or abnormal epigenetic modiﬁcation of the chromatin re-
gion containing theDM1 locus also contribute to pathology (3,11).
Together, alterations in the transcriptome, proteome and re-
plisomemay compromise the physiological integrity of cells and
tissues in which the mutant DMPK and the DM1-antisense gene
are expressed. Throughout development, growth and adulthood
this imbalance may lead to the loss of function and ultimately to
cell degeneration, causing the muscle wasting and CNS white
matter loss in patients (4,12).
For study of biological mechanisms underlying DM1 path-
ology and for testing of possible therapeutic strategies in preclin-
ical studies, several animal models are available, including
Drosophila, zebra ﬁsh and mouse (13,14). Predominant focus is
therebyoriented towardmechanisms involved in RNA-based dis-
ease etiology. Notably, DM1 animal models differ profoundly in
nature, structural organization and chromatin context of their
transgenic insert and in the length of the (CTG·CAG)n segment
therein. Comparison of pathobiological ﬁndings betweenmodels
and extrapolation to the situation in patients remain therefore
difﬁcult. Work of others has already demonstrated that the tim-
ing of DMPK expression, i.e. the onset of potential RNA toxicity,
inﬂuences phenotypic severity (15). Expression of RNA with an
abnormal repeat tract in satellite cells or neuronal progenitor
cells may affect proper muscle and brain development (16–19)
and have serious consequences for tissue regenerative capacity
in adulthood. The absolute number of expanded RNAs and
their structure at any given moment may also be crucial, as
these ultimately will inﬂuence the extent of toxicity caused by
abnormal RNP binding or abnormal properties of RAN translation
products (20–22). The type of gene promoters, whether from
endogenous or ectopic origin, that drive transcription during
development and ageing, and the structure of the transcripts
that entail the repeat segment are therefore critical parameters
in animal models and patients.
Here,we report oncomparisonof expressionandmeasurement
of absolute numbers of (CUG)n-repeat containing RNAs in muscle
cells and tissues of four commonly used mouse DM1 models and
in cells and biopsies from patients. DM1 mouse models express
transgenes with different promoters, different structural organiza-
tion and different repeat lengths: DM500, DMSXL, Tg26 and HSALR
(Table 1). DM500 and DMSXL mice are both descendants of the
DM300-328 line, which was subject to intergenerational repeat ex-
pansion. These mice carry a complete human DM1 locus (23,24).
The DMPK transgene in Tg26 mice carries a tandem insert of ∼25
copies of the complete human DMPK gene, with a normal-sized
(CTG)11 repeat (25,26). In HSALR mice, the transgene is under con-
trol of theACTA1 promoter and the repeat is embedded in the con-
text of the ACTA1 gene (27). The rationale for quantiﬁcation of
repeat RNA expression in these models is that knowledge about
toxic RNA concentration will provide us with more insight in
pathophysiological cascades per se, especially as more and more
anatomical, physiological and behavioral phenotype data become
available, enabling relativelyeasy cross comparisons. Furthermore,
some of the DM1 models have already been extensively used for
preclinical translational studies in the past decade, but translation
of ﬁndings in these models has been difﬁcult.
We demonstrate that, in comparison with expression of nor-
mal and mutant DMPK transcripts in patient cells, considerable
Table 1. Characteristics of DM1 mouse models used in this study.
Mouse model Transgene Transgene
copy
number
Promoter Expression (CTG)n Genetic
background
References
DM500
(DM300-
328 line)
Human DM1 locus
(43 kb transgene)
1 Human DMPK (∼11.5 kb
region upstream of
main TSS)
All DM1-related tissues
(e.g. skeletal muscle,
heart and CNS)
500–600 >90% C57BL/6 (23)
DMSXL
(DM300-
328 line)
Human DM1 locus
(43 kb transgene)
1 Human DMPK (∼11.5 kb
region upstream of
main TSS)
All DM1-related tissues
(e.g. skeletal muscle,
heart and CNS)
∼1300 >90% C57BL/6 (24)
Tg26 Human DMPK gene
(14 kb transgene)
∼25 Human DMPK (∼1.9 kb
region upstream of
main TSS)
All DM1-related tissues
(e.g. skeletal muscle,
heart and CNS)
11 FVB/n (25)
HSALR (LR20b
line)
Human α-actin gene;
CTG repeat inserted
in 3′ UTR (7.1 kb
transgene)
2 Human α-actin (∼2.1 kb
region upstream
of TSS)
Skeletal muscle only 220–250 FVB/n (27)
WT No transgene n.a. n.a. n.a. n.a. >90% C57BL/6 n.a.
TSS, transcription start site; n.a., not applicable.
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variation exists in level and developmental timing of transgene
expression in DM1 cell and animal models. A remarkable low
level of expression with absolute numbers of, at most, a few
dozen RNAmolecules per cell was observed for DMPK transcripts
in human samples. Our ﬁndings highlight the hitherto unrecog-
nized involvement of low-abundance RNA molecules in DM1
pathophysiology, altering our current view on the RNA gain-
of-function theory, which explains the role of repeat RNA in
DM1 manifestation. We discuss the possible implications of our
ﬁndings for future interpretation of data from fundamental and
translational studies in which these DM1 models and patient
cells will be used.
Results
Derivation of myogenic cell lines from DM1 mouse
models
Characteristics of mouse models included in this study are listed
in Table 1. For proﬁling of transgene expression at the cellular
level, we established conditionally immortalizedmyoblast popu-
lations from each model by pooling clones of individual cells
derived from the calf muscle complex from double hemizygous
mice carrying one transgenic DM1 allele and one H-2Kb-tsA58
allele (28). As there is strong evidence that satellite cells from
different inbred mice behave intrinsically differently (29,30),
it is important to note that crossings included different genetic
backgrounds to generate the double hemizygous animals. The
cell populations have therefore distinct mixed genetic back-
grounds with contributions of C57BL6, FVB/n, CBA/Ca and
C57BL/10. We do believe, however, that these differences have
no major impact on transcriptome composition and therefore
should not overtly confound our comparison.
An important feature of the immortalized myoblasts is that
during prolonged passaging in culture under permissive condi-
tions cells have the tendency to undergo polyploidization, as an
effect of the presence of the temperature-sensitive SV40 large
T-antigen (31). This leads to a mix of 2N and 4N cells in popula-
tions of the different lineages and to variation in the absolute
abundance of individual transcripts per cell (Supplementary Ma-
terial, Fig. S1A). Hence, all possible care was taken to compare
myoblasts from similar passage numbers.
DM500, DMSXL, HSALR and WT myoblast populations had
normal morphological appearance and showed apparently nor-
mal proliferative capacity and terminal differentiation features
upon shift to myogenesis-promoting conditions (Fig. 1). Multi-
nuclear contractile myotubes appeared after 3–5 days of differen-
tiation. The Tg26 cell population had normal morphological
Figure 1.Morphology of myoblasts derived from DM1 and control mouse models. Conditionally immortalized myoblasts were derived from the GPS muscle complex of
DM1 mouse models. Myoblasts differentiated into contractile myotubes under low-serum conditions. Representative images of cultures during proliferation (Day -2),
conﬂuency (Day 0) and differentiation (Days 1, 3 and 7) are shown. Bar 100 µm.
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appearance, but showed slightly disordered cell alignment and
diminished fusion capacity upon induction of differentiation.
This may be due to overproduction of certain DMPK protein
isoforms (26,32,33).
To quantify gene expression during proliferation and differen-
tiation of the myoblast populations, RNAwas isolated at various
time points and analyzed by northern blotting and reverse tran-
scriptase–quantitative polymerase chain reaction (RT-qPCR). Pro-
gression ofmyogenic differentiation in vitrowas accompanied bya
clear increase in skeletal muscle α-actin (Acta1) mRNA (Fig. 2A), a
well-known differentiation marker encoding a major constituent
of the contractile apparatus (34–36). The increase was less pro-
found inTg26 cultures, in accordancewith their diminished fusion
capacity.WhereasActa1was induced, β-actin (Actb) expressionde-
creased during the 7-day differentiation period (Supplementary
Material, Fig. S2) (37).
For reference, primary human muscle cells obtained from a
healthy individual and two DM1 patients were also included in
our study. Myoblasts with healthy (CTG)5/(CTG)5 or disease-
speciﬁc (CTG)21/(CTG)200 or (CTG)11/(CTG)760 repeat combina-
tions appeared morphologically diverse, which can be explained
by their different origin and culture history (Fig. 3). Multinu-
cleated myotubes were formed during differentiation, but spon-
taneous contractions were never observed (Fig. 3, data not
shown). RNA expression analysis corroborated this observation
by showing thatACTA1 expressionwasminimal at all time points
measured and remained low in comparison with Acta1 levels in
DM500 GPS tissue (Fig. 4A). We, therefore, conclude that human
cultures did not attain the same endpoint of terminal differenti-
ation as mouse myoblasts under our in vitro conditions.
Transgene expression differs between DM1 myoblast
models
Transgene expression was assayed in the myoblast populations
during proliferation and differentiation (Fig. 2B and Supplemen-
tary Material, Fig. S3). DMPK transgene expression in differentiat-
ing DM500 and DMSXL cells transiently increased 3- to 10-fold
and then returned to basal levels in proliferating myoblasts.
A modest increase in transgene expression was also observed in
differentiating Tg26 myoblasts, but this change appeared to be
more permanent. In contrast, transcript levels from the Dmpk
gene hardly varied with differentiation state in any of the ﬁve
myoblast populations (Fig. 2C). The observed differential regula-
tion of endogenous/transgenic Dmpk/DMPK expression may be
caused by (i) species differences between the structure and func-
tion of Dmpk/DMPK promoters, (ii) differences in the length of
the region upstream of the TSS in the human transgenes used
(Table 1), (iii) differences between chromosomal insert sites and
the endogenous Dmpk locus or (iv) different epigenetic alterations
across the transgenic loci. Inﬂuence of the (CUG)n-repeat length on
RNA stability is unlikely, because temporal proﬁles of transgenic
RNA expression in DM500 and DMSXL cells during myogenic
differentiation levels were highly similar.
ForDMPK expression in humanmyoblasts, we performed sep-
arate quantitative analysis of healthy and expanded transcripts,
whichmigrate differentially on northern gels. Steady-state levels
of normal and expanded DMPK RNA molecules were approxi-
mately similar for both the 21/200 and the 11/760 patient cell cul-
tures (Fig. 4B). Comparison of total DMPK expression levels
between healthy 5/5 and patient cell cultures showed variation.
Figure 2. Expression proﬁle of proliferating and differentiatingmyoblasts derived fromDM1 and controlmousemodels. Analysis of endogenousActa1 (A), transgene (B) and
endogenous Dmpk (C) mRNA levels by northern blotting. Each hybridization signal was normalized to that of 18S rRNA and then compared with the normalized value
measured for the same (trans)gene in the GPS muscle from that particular DM1 mouse model. Data were obtained from two independent culture series per cell line, for
which triplicate cultures per series were pooled and analyzed; bars represent mean + SEM. For proﬁling of endogenous Dmpk (C) in Tg26 samples RT-qPCR was used,
because signals of transgenicDMPK and endogenousDmpkoverlapped onnorthern blot. Bars representmean+ SEM. Timing of differentiation on thex-axis refers to Figure 1.
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However, temporal proﬁles had a similar shapewith a peak in ex-
pression during early differentiation, alike expression behavior of
DMPK transcripts from the DMPK transgene in mouse myoblasts.
This supports our idea that species-speciﬁc differences in the
DMPK/Dmpk promoter explain the differential expression pattern
of DMPK and Dmpk transcripts.
For better interpretation of in vitro and in vivo ﬁndings, we com-
pared DMPK transgene expression in myogenic cultures to that in
parental GPS muscle in the DM1 models. Transgene expression
was ∼0.6- to 6-fold higher, 6- to 18-fold higher and 3- to 11-fold
lower for DM500, DMSXL andTg26myoblast/myotube cultures, re-
spectively (Fig. 2B). Of particular, interest was the expression pro-
ﬁle of the expanded ACTA1 transgene in differentiatingmyoblasts
from the HSALR model, showing that transcripts were expressed
only late in differentiation (Fig. 2B). Even in fully differentiated
hemizygous HSALR myotubes in vitro, expanded ACTA1 transgene
expression remained ∼200-fold lower than in GPS muscle from
homozygous HSALR mice.
Figure 3. Morphology of primary human DM1 and healthy myogenic cells. Human primary myoblasts aligned and fused under low-serum conditions. Representative
images at different time points during proliferation (Day -2), conﬂuency (Day 0), and differentiation (Days 1, 3 and 7) are shown. The number of CTG triplets for the
two DMPK alleles are indicated for the one healthy (5/5) and two DM1 (21/200 and 11/760) cultures. Bar 100 µm.
Figure 4. Expression proﬁle of proliferating and differentiating primary human DM1myogenic cells. Assessment of ACTA1 (A) and DMPK (B) transcript levels by northern
blot analysis. Signal strength in each sample was normalized to that of 18S rRNA, as outlined in the legend of Figure 2. To facilitate direct comparison with DM1 mouse
model-derived myoblasts, ratios were related to Acta1 and Dmpk levels in DM500 GPS muscle. Data were obtained from two independent culture series per cell line, for
which triplicate cultures per serieswerepooled andanalyzed; bars representmean + SEM. Stacked bar graphs show levels of normal-sizedDMPK (black part) and expanded
DMPK (white part) in patient-derived cultures. On average, the ratio expanded versus normal-sized DMPK transcripts was 0.63 for 21/200 and 0.84 for 11/760. Timing of
differentiation on the x-axis refers to Figure 3.
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Transgene expression in distinct DM1 mouse models
differs over a 1000-fold range
By extending our analysis to mouse muscle in vivo, using the GPS
complex as RNA source and 18S rRNA for normalization, our
comparison revealed thatActa1 expressionwas remarkably simi-
lar betweenmodels (Fig. 5 and SupplementaryMaterial, Fig. S4A),
despite differences in their genetic background (Table 1). Also
Dmpk expression showed only minor ﬂuctuations. Whereas
Acta1 and Dmpk expression did not vary >2- to 4-fold between
mouse models, the mean level of Acta1 RNA was ∼2,500-fold
higher than that of Dmpk RNA.
We next compared transgene expression in GPS muscles from
DM500, DMSXL and Tg26 mice. Quantiﬁcation was straightfor-
ward, since all models expressed differentially expanded, but
otherwise similar and intact DMPK transgenes. Transgenic DMPK
RNA accumulated in muscle from hemizygous DM500 and
DMSXLmice to a 10-fold lower level than RNA from the endogen-
ous Dmpk genes (Fig. 5). In contrast, hemizygous Tg26 GPSmuscle
expressed 20- to 25-foldmore DMPKmRNA than DmpkmRNA [as-
suming that Dmpk expression in Tg26 mice (FVB background) was
similar to that in DM500 mice (C57BL/6 background)]. Determin-
ation of relative levels of transgenic RNA in HSALR muscle ap-
peared more challenging. Use of a (CAG)9 probe to detect (CUG)n
segments, the onlysequence sharedbetween transgenic products,
proved unreliable to compare RNAs with different repeat lengths
(data not shown). Therefore, a balanced mix of ACTA1 and DMPK
probes, generated by random-primed labeling on cDNA templates
of equal size was used instead (see the Materials and Methods’
section). With this approach we found ACTA1 (CUG)n RNA over
1000-fold higher expressed than Dmpk mRNA in homozygous
HSALR mice (Fig. 5). This means that the concentration of ex-
panded transcripts in HSALR muscle is extraordinarily high and
similar to that ofActa1mRNA. This ﬁnding is perhaps not too sur-
prising as both promoter and backbone of the human transgene
and the Acta1 gene share strong homology.
Analysis of DMPK RNA levels in human muscle allows
direct interpretation of transgene dosage
Skeletalmuscle samples fromhealthy humans andDM1patients
were included in our study to extend our comparisons. DMPK
mRNA expression in the samples varied, but was not >3-fold
higher than the level of Dmpk mRNA in mouse GPS tissue
(Fig. 6). Expression of normal-sized and of expandedDMPK alleles
were about equal in each of the patient samples. Since DMPK le-
vels in human muscles and Dmpk levels in mouse muscle show
high similarity, observations about transgene expression dosage
effects in DM1 mice may be directly translated to relevance for
DM1 patients. Any difference in DMPK mRNA content between
human samples probably represents variation in ﬁber type and
muscle origin or must be caused by differentiation or disease
state. Note that, effects of ageing on repeat length heterogeneity
were clearly visible on northern blot: in samples from adult DM1
patients a smear was observed for RNA from the expanded allele,
whereas in congenital DM (CDM) patient material a deﬁned sig-
nal was apparent (Fig. 6) (38).
Multi-pronged analysis reveals low copy number
of expanded DMPK transcripts
For further stoichiometric and pathomechanistic considerations,
we decided to determine the absolute number of DMPK mRNA
copies per cell. Quantiﬁcation on northern blot, after normaliza-
tion for signal strength and correction for probe length, revealed
thatDMPK/Dmpkexpressionwas 400- to 2000-fold lower than that
of ACTB/Actb in proliferating human/mouse myoblasts (Fig. 7A
and Supplementary Material, Fig. S4B). Based on known values
for the copy number of ACTB/Actb mRNA, which ranges from
350 to 8000 per cell (39–42) (Supplementary Material, Table S1),
we inferred that the absolute number of DMPK transcripts must
be in the range of 1–20 per cell. In patient myoblasts, this popula-
tion consists of approximately equal numbers of normal-sized
and expanded DMPK transcript molecules (Figs. 4 and 7A).
To validate this rough estimate, DMPK RNA copy number was
quantiﬁed using two in vitro transcribed DMPK RNAs as standard
references in RT-qPCR (Supplementary Material, Fig. S5). We
found 20–25 DMPK transcripts per proliferating 11/760 myoblast
and 45–50 DMPK molecules in myoblasts just prior to the onset
of myogenic differentiation (Fig. 7B). This number includes both
healthy and expanded DMPK transcripts. On average about four
expanded DMPK transcripts per cell were detected in DM500
myoblasts.
Thirdly, we used RNA-sequencing data of healthy and DM1
skeletal muscle (available via www.dmseq.org) to estimate DMPK
transcript copy number. We calculated the DMPK:GAPDH ratio
based on RNA-sequencing signal and found thatDMPKmRNAmo-
lecules were 60- to 160-fold less abundant than GAPDH mRNA
(Fig. 7C). Based on current estimates for the prevalence of GAPDH
RNA, which is in the order of 250–2900 molecules per cell (39,42–
45) (SupplementaryMaterial, Table S2),DMPK transcript copynum-
ber must be between 2 and 50 per cell.
Finally, we determined the number of ﬂuorescent in situ hy-
bridization (FISH)-detectable RNP complexes in mouse and
human myoblasts using a Cy3-labeled (CAG)7 probe. Initial
Figure 5. Transgene expression in DM1 mouse skeletal muscle. Expression of Acta1, Dmpk and transgenes was determined in GPS muscle of each DM1 mouse model.
Transcripts were quantiﬁed by northern blotting using 18S rRNA for normalization (n≥ 4). Endogenous Dmpk RNA levels in DM500 GPS muscle were used as reference
(set to one). Mean + SEM are shown. a.u., arbitrary units; n.d., not determined (Dmpk and transgenic signals overlap); n.a., not applicable.
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analyses demonstrated that the number of FISH signals slightly
varied between myoblast pools and experiments and was inﬂu-
enced by culture conditions, such as cell density, feeding regime
or changes in the culture medium (data not shown). This vari-
ation in foci number appeared suppressible by maintaining a
very strict scheme for cell culture. On average, 5–9 foci per cell
were detected in DM500 myoblasts (Fig. 8A and B). The number
of foci differed between diploid and tetraploid DM500 myoblasts,
with averages of ∼5 and ∼9 foci per cell, respectively (Supplemen-
taryMaterial, Fig. S1B). For reasons unknown, we also consistent-
ly observed signals inWTmousemyoblasts (Fig. 8A and B). These
signals could not be distinguished from expanded DMPK (CUG)n
mRNA signals and may also be present in other cell types from
mouse. In cells from human origin, we did not observe overt
background signals, so the problem may be species speciﬁc. To
deal with this issue, we decided to apply a correction by deﬁning
a background interval in Figure 8. After this correction, an aver-
age of two transgenic expanded (CUG)n-speciﬁc foci per cell re-
mained in DM500 myoblasts. Foci counts in Tg26 and HSALR
myoblasts were within the background range, as expected,
based on the idea that the (CTG)11 repeat in Tg26 RNA cannot
yield sufﬁcient signal and our ﬁnding that the HSALR transgene
is barely expressed in proliferating myoblasts. In 11/760 patient
myoblasts 3–4 foci per nucleus were detected, whereas no signal
was observed in 21/200 and 5/5 myoblasts (Fig. 8C and D), obvi-
ously caused by lack of FISH-signal strengths by the limited
length of the repeat target.
All data combined, we conclude that mouse and human myo-
blasts each contain up to half a dozen foci. We have to keep in
mind that FISHprotocolsmay detect transcriptswith an efﬁciency
of only 30–50% (41), for example, due to inaccessibility of the tran-
scripts to the probe or loss of RNA molecules from the ﬁxed cells
during washing. Thus, the actual number of RNP complexes that
appear as foci may be 2- to 3-fold higher. Given our estimates for
the absolute number of expanded transcripts, our data suggest
that every RNP complex that forms a FISH-visible aggregate is nu-
cleated by one or only few expanded (CUG)n transcripts.
Discussion
DM1 is considered a prototypical RNA-dominant disorder, be-
cause its neurodegenerative and myopathic manifestation is
thought to be based on processes wherein repeat-containing
RNAs play a crucial role. Much of our current knowledge on the
presumed toxic role of RNA in DM1 pathophysiology originates
from direct comparison of ﬁndings in mutation carriers with
ﬁndings in transgenic animals or genome edited cells. This is
often donewith simple bypassing of the fact thatmodelsmaydif-
fer profoundly in nature, structural organization and chromatin
context of the transgene and in length of the contained
(CTG·CAG)n repeat (13,14). A major unsolved aspect of DM1 eti-
ology is how repeat length and dose and nature of abnormally ex-
panded RNA transcripts affect onset and complexity of disease
manifestation and its rate of progression and severity. Quantita-
tive studies of transcript production could thus help to explain
differential experimental ﬁndings with distinct DM1 models
and add to conceptual progress. Here, we used gene expression
proﬁling to compare relative abundance and absolute copy num-
ber of expanded repeat RNAs betweenmuscle cells from patients
and mouse models that are among the most commonly used in
the DM1 ﬁeld.
Our analyses unveiled differences in timing of production
during myogenic differentiation as well as in the abundance of
(CUG)n transcripts between DM1 mouse model and patient mus-
cle cells. Expression of DMPK transgenes in DM500, DMSXL and
Tg26 mice is at a basal level in proliferating myoblasts and
peaks early in differentiation in a manner similar to the proﬁle
of endogenous DMPK expression in human myoblasts. Increase
in DMPK expression at the start of myogenic differentiation was
earlier reported for human cells (46) and also seen for C2C12
Figure 6.DMPK expression in human control andDM1patient tissue. Northern blot (left) of human control andDM1muscle tissue using aDMPK and a (CAG)9 repeat probe.
HealthyDMPKmRNAappeared as a deﬁned band in all tissues. ExpandedDMPKmRNAappeared as a deﬁned band in congenital DM1 tissue (CDM-e and -f), but as a smear
(representing somatic mosaicism of repeat size) in adult DM1 tissue (DM1-c and -d). As size markers, we indicated the location of DMPK (CUG)700 and (CUG)1300
transcripts. DMPK transcript levels, normalized to those of 18S rRNA, were plotted relative to Dmpk transcript levels in DM500 GPS muscle to allow for comparison
with DM1 mouse models (right). Stacked bar graphs show levels of normal-sized DMPK (black part) and expanded DMPK (white part) in patient-derived samples.
The ratio expanded versus normal-sized DMPK transcripts was 0.33 in DM1-c; 0.92 in DM1-d; 0.84 in CDM-e and 1.79 in CDM-f.
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mouse myoblasts (47). Our group (25) and others (32) have
demonstrated that the actual onset of DMPK expression is
already seen in somites in the developing embryo, well before
the actual commitment to speciﬁc muscle cell fate and the
onset of myogenesis.
DM500/DMSXL- andTg26-derivedmyoblasts carry transgenes
of different size that may lack regulatory elements upstream of
the DMPK TSS, but the proximal promoter sequence and the
enhancer sequence in Intron 1 (elements responsive to MyoD
via conserved E-boxes (48)), are present. Thus, regulatory se-
quences from the human locusmay drive ‘near-natural’ behavior
of these transgenes and control the peak-shaped up-regulation
with transient increase in transcriptional activity during early
differentiation. The ‘human-like’ regulation of the DMPK trans-
gene renders these mouse myoblasts useful models for study of
toxic effects of normal or expanded DMPK RNA in early develop-
ment. Others have demonstrated that early-onset expression of
repeat-containing RNA may inﬂuence phenotypic severity by
affecting proper tissue development in animals in vivo (16–19).
InHSALRmyoblasts, expression of repeat-containing RNAwas
hardly detectable until late in differentiation in vitro. Conspicu-
ously, the Acta1 gene, whose human counterpart served as the
recipient body for the transgene with (CTG)250 repeat insertion,
showed an earlier onset of expression in differentiating mouse
cells. The explanation for this differential behavior may thus be
that the proximal promoter is present in the transgene, but that
a cis-regulatory module in a region that activates transcription in
differentiating myoblasts, >20 kb downstream of the basal
promoter (49), is lacking.
We found pronounced differences in the abundance of (CUG)n-
repeatRNAs fromtransgenesandRNAproducts fromtheendogen-
ousDmpk geneandbetweenexpandedRNAs fromcell lineages and
the transgenicmouse tissues fromwhich they originate. For prolif-
erating cells, comparison was only meaningful for Tg26, DM500
and DMSXL myoblasts, as HSALR myoblasts essentially lacked ex-
pression of expanded (CUG)n RNA. As explained by the presence
of multiple copies of the DMPK gene in the transgenic insert in
Tg26 cells, DMPK levels were relatively high. Transcripts from the
Figure 7. DMPK RNA copy number in human and mouse myoblasts. The absolute number of DMPK transcripts per cell was calculated based on experimental data from
northern blotting (A), RT-qPCR (B) and RNA-sequencing (C). (A) Stacked bar graph showing DMPK/Dmpk:ACTB/Actb transcript ratios determined from signal strengths on
northern blots for humanmyoblast lines 5/5, 21/200 and 11/760, and mousemyoblasts lines WT and DM500 (Supplementary Material, Fig. S4B). (B) DMPK transcript copy
number in 11/760 and DM500myoblasts was determined on the basis of known amounts of syntheticDMPK RNA fragments in RT-qPCR (SupplementaryMaterial, Fig. S5).
Note that, normal-sized and expanded DMPK transcripts could not be measured independently. (C) DMPK:GAPDH ratio based on RNA-sequencing signal of healthy and
DM1TAandquadriceps (Quad) tissue (www.dmseq.org). Each data point represents a single tissue.Mean + SEM (AandB), ormeanonly (C) are shown.Descriptions d-2 and
d0 refer 938 to Figures 1 and 3.
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DMPK transgene in DM500 and DMSXL cells were ∼10-fold lower
than transcripts from the Dmpk gene in these myoblasts. Even if
we take into account that these observations reﬂect the production
rate from one DMPK transgene versus two Dmpk genes in the
DM500 cell model, transgenic RNA production is still ∼5-fold
lower. Intrinsic differences in regulatory capacity of DMPK and
Dmpk promoters may partly explain this observation, but we can-
not exclude involvement of progressive epigenetic alterations,
like DNA methylation or heterochromatization of the transgene
or theDMPKpromoter. Brouwer et al. (50) observeddecreased trans-
gene expression with age in the DM300-328 lineage, the ancestral
mouse model from which DM500 and DMSXL mice and thus
DM500 and DMSXL cells originate. Cis effects of repeat presence
may have contributed to methylation state alterations in the
DMPK transgene (50). Also transient propagation of mice in the
homozygous state may have triggered partial gene silencing even
before the myoblasts were derived in vitro (51–53). Finally, we can-
not exclude effects of experimental handling, for example, by the
Figure 8. (CUG)n foci number in DM1mouse and humanmyoblasts. Representative RNA FISH images using a (CAG)7 oligo probe (A and C) and quantiﬁcation (B and D) of
(CUG)n foci in DM1 mouse and human myoblasts. (A and B) RNA FISH signal in WT and DM500 myoblasts. In WT mouse myoblasts foci were observed which cannot be
speciﬁc for the transgenic expanded (CUG)n transcripts. As these signals may also be present in cell lines derived from other mouse lineages, including the transgenic
models, we deﬁned a level of uncertainty, plotted as a shaded area in (B). Thus, an average of two expanded (CUG)n-speciﬁc foci per cell remained in DM500 myoblasts
and no speciﬁc foci were identiﬁed in Tg26 and HSALR myoblasts. (C and D) RNA FISH on human healthy (5/5) and DM1 (21/200 and 11/760) myoblasts. Foci were only
detected in 11/760 cells. Each data point represents foci number in one nucleus; mean is plotted in graph. Bar 20 µm. ***P < 0.001.
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use of dimethylsulfoxide during repeated cell freezing, which can
affect the epigenetic state and is a knownmodulator of differenti-
ation programming (54). Although we did not systematically study
expression levels over time, we have the impression thatDMPK ex-
pression inDM500 cells decreaseswith increasingpassagenumber
[compare data shown in (55)]. This could point to the inﬂuence of
epigenetic silencing, explaining also variability in observations of
different research groups in the DM1 ﬁeld.
Also in muscle tissue obtained from hemizygous DM500 and
DMSXL mice DMPK transcripts were 10-fold less abundant than
Dmpk RNAs, conﬁrming the observation by Huguet et al. (56).
The overall low level of transgene expression may explain why
disease manifestation in these models is relatively mild, even
in homozygous animals. Conversely, however, one can also
argue that the presence of these few expanded RNAs is already
sufﬁcient to cause mild myotonia, slow progressive muscle
weakness, nuclear (CUG)n foci and splicing abnormalities
(1,14,57), for which compelling evidence was provided in various
studies.
Ourmost conspicuous observationwas thatACTA1 (CUG)n ex-
pression in GPS muscle of homozygous HSALR mice was over
1000-fold higher than that of Dmpk, and remarkably similar to
Acta1 expression. The high (CUG)n RNA expression may explain
why the HSALR mouse lineage has by far the most severe DM1-
like phenotype of all models, including myotonia, extensive
splice abnormalities and a conspicuous abnormal density of in-
tranuclear foci, all limited to skeletal muscle (1,14,27).
The use of expression ratios between transgenic and en-
dogenous transcripts (e.g. Dmpk, Acta1, Actb and 18S RNA) helped
us to compare repeat RNA levels between muscle cells and
mouse and human tissues, but we reasoned that the knowledge
of absolute transcript copy numbers in muscle would be mech-
anistically more informative. Absolute numbers of molecules
can only be meaningfully assessed if studied on a per cell basis.
Analysis of DMPK expression in the three human myoblast
lineages with no, intermediate or long repeat expansions con-
ﬁrmed that transcripts from the wild-type and mutant allele
are about equally abundant.We found no evidence for an inverse
correlation between repeat the length and RNA expression level
(46,58). Because endogenous DMPK/Dmpk transcripts appeared
equally abundant in human and mouse myoblasts, quantitative
comparison between patients and DM1 models was straightfor-
ward. Estimates for RNA expression ratios of ACTB and GAPDH,
data from northern blot and RNA-sequencing analysis and abso-
lute RT-qPCR experiments all point to the presence of at most 50
DMPK transcripts per cell. We thus propose that in patient cells
<25 are expanded (CUG)n transcripts. In myoblasts from the
DM500 and DMSXL mouse models around four RNA molecules
per cell originate from the DMPK transgene.
Estimates for DMPK transcript numbers correspond remark-
ably well with the observed foci number in DM500 cell nuclei.
Also in patient myoblasts the number of foci per nucleus and
the number of DMPK transcripts per cell are in the same order
of magnitude. Other research groups, studying different cell
types from DM1 patients, have reported similar amounts of foci
from their FISH experiments (59–62). Different and variable
amounts of foci were observed for MyoD-transduced DM1 ﬁbro-
blasts, which may be best explained by the distinct MyoD induc-
tion ofDMPK expression, caused by differential vector systems or
MyoD promoters (60,63). We, therefore, predict that RNP com-
plexes that assemble in (CUG)n foci contain, on average, one to
maximally six expanded transcripts. Along the same line of argu-
ments, we propose that RNP aggregate formation is nucleated by
one or very few expanded RNA molecules, thereby acting as
individual entities. Phase transition of RNP complexes to insol-
uble aggregates (which appear as foci after FISH or MBNL anti-
body staining) may therefore not require further fusion with
additional naked or RNP-decorated RNAs, but could be merely a
protein-based event.
Many mechanistic avenues are now awaiting further ex-
ploration as our ﬁndings have important implications for the
RNA-gain-of-function hypothesis that is currently in use for ex-
plaining DM1 features. How low numbers of only 1–25 abnormal-
ly folded RNA scaffolds can have a negative impact on ribostasis
regulation—via titration of protein molecules from the total
available pools of RNP proteins—is only one of the mechanistic
questions that must be answered. The extent of loss of function
of proteinsmay determine the gain of function toxicity ofmutant
RNA—and ultimately control the extent of cell stress caused by
the DM1 mutation. Whether there is a direct relationship with
the magnitude of temporal or permanent sequestration from
the cellular pool of these RNP proteins is still difﬁcult to answer.
Stochastic events could be involved, as formation of an abnormal
type of—microscopically visible or invisible diffusive—RNP ag-
gregate on a repeat-containing transcript (6,7) might cause tem-
poral or permanent perturbation of a speciﬁc nuclear pathway for
mRNA processing or transport. Dominant effects of low-abun-
dance triplet repeat RNA on RNA splicing and polyadenylation
may be expected if effects on inhomogeneity and compartmen-
talization of protein factor pools (e.g. MBNL isoforms) in different
nuclear trajectories for mRNA RNP processing play a decisive
role. Finally, ampliﬁcation of toxic effects by rare triplet repeat
RNAs may occur otherwise: various studies have demonstrated
that activation of stress-signaling cascades that involve GSK3β
(64), PKC (65), double-stranded RNA-dependent protein kinase
PKR (66) or sensors of foreign RNA that normally initiate immune
responses (67) is involved in disease manifestation in DM1.
Whatever the exact course of cellular events in these scenarios,
even with low-expressed, abnormally expanded repeat RNAs
the probability of exceeding the toxic threshold increases over
time for any permanently expressing cell in the tissue popula-
tion. Ultimately, this may result in accumulation of stress in an
increasing number of cells, and progressive cell loss and loss of
function of tissue during ageing.
In a parallel study, we have recently found that expression of
another possible player, a DM1 antisense transcript carrying a
(CAG)n repeat, is even 10-fold lower than levels observed for
DMPK (Gudde et al. manuscript in preparation). Thus also here,
the question remains how such an extremely rare transcript
could contribute to disease manifestation. One unifying answer
may be that the rare DMPK sense RNA and the even rarer anti-
sense transcript both serve as templates for RAN translation
(9,10). Homopolymeric protein products thus formed could pos-
sibly contribute to disease manifestation via initiation of aggre-
gation of metastable proteins, initiating a prion-like cascade of
events (68–70). Again, further analysis of steady-state levels of
DMPK (CUG)n and antisense transcripts in cycling or resting
cells and study of the frequency of use of RAN translation on
these rare RNAs is necessary to better understand this possible
distinct aspect of DM1 etiology.
Our ﬁndings highlight that careful choice of cellular and ani-
mal model systems that take structural properties of transgenes
and transgenic products into account in combination with quan-
titativemodeling is imperative for such studies. For this work not
only knowledge of the ‘per cell’ presence of individual endogen-
ous and mutant RNA molecules is important, but also stoichio-
metric considerations on the binding of MBNL1–3, Staufen,
DDX, HnRNP or other RNP proteins (7) by one (CUG)n repeat
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tract are needed to better understand nucleation and phase tran-
sition events in abnormal aggregates that could form around ex-
panded DMPK mRNAs. Whatever the molecular mechanism
involved, based on our ﬁndings, we propose that DM1 is caused
by anomalous behavior of only very few mutant RNA molecules
per muscle cell.
Materials and Methods
Human material
Human skeletal muscle samples were obtained from pre-con-
sented post-mortem donors for research purposes in accordance
with local guidelines in The Netherlandsmore than 18 years ago.
No additional approval by an ethics committee was required at
that time. Muscle autopsies were obtained from patients with a
conﬁrmed clinical and DNA diagnosis of adult-onset DM1 [male
DM1-c, 55 years, psoas muscle (CTG)5/(CTG)exp; female DM1-d,
65 years, quadriceps muscle (CTG)16/(CTG)exp] and congenital
DM1 [male CDM-e and -f, 14 days, sternocleidomastoideus and
gastrocnemius muscle (CTG)12/(CTG)1300]. All tissues were
snap frozen immediately after collection and stored at −135 to
80°C until further use. As control, skeletal muscle samples from
healthy anonymous donors [healthy-a and -b (CTG)11/(CTG)12
and (CTG)5/(CTG)11, respectively] from our own repository were
included in our study. These samples were collected long before
the current guidelines for written consent were enforced and no
detailed information could be traced.
Mice
Mice were housed and procedures performed with approval of the
Animal Ethics Committee of RadboudUniversityNijmegen (Permit
number: RU-DEC 2014-099). Characteristics of the mouse models
are summarized in Table 1. DM500 and DMSXL mice both origi-
nated from the DM300-328 lineage (23). Due to intergenerational
triplet instability the repeat in the DMPK gene grew to 500–600
and ∼1300 CTG triplets in DM500 and DMSXL mice, respectively
(24). For isolation of immortalized myoblasts, each of the DM1
mouse models was crossed with hemizygous H-2Kb-tsA58 trans-
genic mice (ImmortoMouse®, Charles River Laboratories) (71), har-
boring the gene for thermolabile TAg fromSV40. Nine-dayold pups
carrying one DMPK or ACTA1 transgene copy and one H-2Kb-tsA58
transgene copy were selected and used for myoblast generation.
Cell culture
Conditionally immortalized myoblasts from the gastrocnemius–
plantaris–soleus (GPS) muscle of DMSXL, Tg26 and HSALR mice
after crossing with H-2Kb-tsA58 mice were derived as described
(28,55,71). Individual myoblast lineages were obtained by ring
cloning and selected for myotube formation ability. Myoblast po-
pulations used in this study were established by forming equal
mixtures of ﬁve cell clones for DMSXL, seven cell clones for
Tg26 and four cell clones for HSALR. DM500 and WT myoblasts
were derived previously (55).
Myoblasts were grown on 0.1% (w/v) gelatin-coated culture
dishes in the proliferation medium containing Dulbecco’s modi-
ﬁed Eagle’smedium (DMEM) (Gibco) supplementedwith 20% (v/v)
fetal bovine serum (PAA Laboratories), 4 m -glutamine (Gibco),
1 m pyruvate (Sigma), 50 µg/ml gentamicin (Gibco), 20 units/ml
γ-interferon (BD Biosciences) and 2% (v/v) chicken embryo extract
(Sera Laboratories International) at 7.5% CO2 and 33°C. Differenti-
ation to myotubes was induced by placing myoblasts, grown to
conﬂuency on Matrigel (BD Biosciences), in the differentiation
medium containing DMEM supplemented with 5% (v/v) horse
serum and 50 µg/ml gentamicin at 7.5% CO2 and 37°C. Differenti-
ation conditions were maintained for a maximum of 7 days.
Spontaneous contractions started to appear around Day 3.
Human myoblast cultures isolated from skeletal muscle of fe-
tuses, one healthy control (5/5) and two DM1 affected lines [21/200
with (CCG·CGG)n interruptions in the 3′ end of the expanded
(CTG·CAG)n repeat; data not shown] and 11/760 were a gift of Dr
Furling et al. (46). Myoblasts were maintained on 0.1% (w/v) gel-
atin-coated culture dishes in proliferation medium containing
Ham’s F10 medium (Gibco) supplemented with GlutaMAX, 20%
bovinegrowth serum (ThermoScientiﬁc) and25 µg/ml gentamicin
at 7.5% CO2 and 37°C. Differentiation to myotubes was induced by
placing conﬂuentmyoblast cultures in the differentiationmedium
containing DMEM supplemented with 4 m -glutamine, 1 m
pyruvate, 10 μg/ml insulin (Sigma), 100 μg/ml apo-transferrin
(Sigma) and 25 μg/ml gentamicin.
Phase contrast images of cell cultures were taken with a Zeiss
Axiovert 35 M light microscope, 10×/0.30 objective.
Fluorescence-activated cell sorting
Immortalized WT mouse myoblasts were detached from the cul-
ture surface using trypsin, washed in phosphate-buffered saline
(PBS) and ﬁxed in 70% (v/v) ethanol in PBS overnight at −20°C.
After two times PBS wash, cells were stained in 20 µg/ml propi-
dium iodide, 0.2 mg/ml RNase A, 0.1% Triton X-100 in PBS for
15 min at 37°C. Fluorescence-activated cell sorting analysis was
performed on the Beckman Coulter Epics Altra cell sorter. Immor-
talizedDM500myoblastswere cultured in proliferationmediumat
37°C for 24 h, detached and incubated with 3 µg/ml Hoechst 33342
at 37°C for 30 min and then sorted. Diploid and tetraploid DM500
cells were seeded on gelatin-coated glass cover slips, cultured for
another 24 h at 37°C and analyzed by FISH.
RNA isolation
RNA from cultured cells was isolated using the AurumTotal RNA
Mini Kit (Bio-Rad), according to themanufacturer’s protocol. RNA
from muscle tissue was isolated using TRIzol reagent (Invitro-
gen), according to the manufacturer’s protocol.
Northern blotting
Northern blotting was performed according to standard proce-
dures. RNA was subjected to electrophoresis in a 1.2% agarose
gel under denaturing conditions. Depending on sample availabil-
ity, 5–12 µg RNAwas loaded per lane. RNAwas transferred to Hy-
bond-XL nylon membrane (Amersham Pharmacia Biotech) by
capillary transfer in 10× SSC andhybridizedwith random-primed
32P-labeled cDNA-based probes or 32P-end-labeled oligonucleo-
tides: a 2.6 kb DMPK cDNA (covering the entire ORF and 3′ UTR)
(55) and the complete 1.9 kb human 18S rRNA cDNA were used
as templates in random priming reactions. A (CAG)9 oligo (55), a
Acta1 oligo (5′-ACCCTGCAACCACAGCACGATTGTCGATTG-3′) (72)
and a mixture of three oligos complementary to both Acta1 and
ACTA1(5′-GCGGTGGTCTCGTCTTCGTCGCACAT-3′, 5′-TGGCATAC
AGGTCCTTCCTGATGTCGATGTC-3′, 5′-GCCTCGTCGTACTCCTGC
TTGGTGATCC-3′) were 5′-end labeled. The Acta1/ACTA1 oligo
mix and the DMPK cDNA probe were used to quantify ACTA1
andDMPKmRNA levels, respectively, in human samples. Inmur-
ine samples, the single Acta1 oligo, DMPK cDNA and (CAG)9 oligo
probes were used to quantify Acta1, Dmpk and transgenic DMPK
(DM500 and DMSXL) and transgene (Tg26 and HSALR) mRNA
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levels, respectively. Blots were washed and exposed to X-ray ﬁlm
(Kodak, X-OMATAR). Quantiﬁcation of signals was performed by
phosphor-imager analysis (Molecular Imager FX, Bio-Rad) and
analyzed with Quantity One (Bio-Rad) and FIJI (73) software. 18S
rRNA levels were used for normalization.
To be able to compare transgene expression in the DM1mouse
models, carryingdifferent transgenes (i.e.DMPK- orACTA1-type), a
mix of ACTA1 cDNA probe (1.3 kb, Exon 2–7, 27% G-content) and
DMPK cDNA probe (1.3 kb, Exon 3–12, 34% G-content) was used.
Both genes are ∼90% identical between mouse and human, so
simultaneous detection of endogenous and transgenic transcripts
was possible. [α-32P]-dCTP label was diluted with non-radioactive
dCTP for labeling of the ACTA1 probe to obtain comparable signal
strengths for simultaneous phosphor-imager detection of Acta1/
ACTA1 and Dmpk/DMPK on the same blot. Signals were corrected
for label dilution and G-content in the two probes. Since ACTA1
and Actb are 84% identical, the ACTA1 probe was also used for
detection of Actb. A similar method was used to compare DMPK/
Dmpk and ACTB/Actb expression. A 1.3 kb ACTB cDNA probe was
used (Exon 1–6, 27% G-content), which has a 90% identical
sequence with the mouse variant.
In vitro transcription
DNA templates corresponding to DMPK regions Exon 1–6 (0.6 kb)
and Exon 11–15 (1.0 kb) were generated by PCR using primers
5′-GAATTTAATACGACTCACTATAGGGAGAGGCGGCTCCAGCAG
C-3′ and 5′-CCGCAGCTTGA-GGCAAGAG-3′, and 5′-GAATTTAAT
ACGACTCACTATAGGGAGATGGAGGCCATCCG-3′ and 5′-GTCCT
GTAGCCTGTCAGCGA-3′, respectively (T7 promoter underlined).
DNA purity and sequence identity were conﬁrmed by sequen-
cing. For in vitro transcription, 200 ng of the templates was used
in the MEGAscript T7 Transcription Kit (Ambion) following man-
ufacturer’s instructions. RNA products were puriﬁed using the
Aurum Total RNA Mini Kit (Bio-Rad). Transcript length, purity
and concentration were veriﬁed by gel electrophoresis and
absorbance at 260/280 nm (NanoVUE spectrophotometer, GE
Healthcare Life Sciences). Known amounts of RNA fragments
DMPK Exon 1–6 and Exon 11–15 were mixed with WT mouse
total RNA (as carrier RNA) and used as standards in RT-qPCR.
Reverse transcriptase–quantitative polymerase chain
reaction
Using 500 ng RNA template per reaction and random hexamers
as primers, cDNA synthesis was performed with SuperScript™
II Reverse Transcriptase (Invitrogen) or iScript™ cDNA Synthesis
Kit (Bio-Rad). For RT-qPCR, 3 µl of 10–100-fold diluted cDNA prep-
aration was mixed in a ﬁnal volume of 10 µl containing 5 µl
2× Sybr Green mix (Roche Applied Science) or 5 µl iQ™ SYBR®
Green Supermix (Bio-Rad) and 4 pmol of each primer: DMPK
Exon 1–2: 5′-ACTGGCCCAGGACAAGTACG-3′ and 5′-CCTC
CTTAAGCCTCACCACG-3′; DMPK Exon 15(5′): 5′-AGAACTGTCTTC
GACTCCGGG-3′ and 5′-TCGGAGCGGTTGTGAACTG-3′; ACTA1:
5′-CACCTCCAGCACGCGACTT-3′ and 5′-CGATGGCAGCAACGGAA
GTTGT-3′; Dmpk: 5′-TTTTGAAGGTGATCGGGCGTG-3′ and 5′-CCT
CTCTTCAGCATGTCCCACTTA-3′; 18S rRNA: 5′-GTAACCCGTTG
AACCCCATT-3′ and 5′-CCATCCAATCGGTAGTAGCG-3′. Samples
were analyzed using the CFX96 Real-time System (Bio-Rad).
Amelting curvewas obtained for each sample in order to conﬁrm
single product ampliﬁcation. cDNA samples from no template
control and no reverse transcriptase control (RT-) were included
as negative controls. Transgene (DMPK andACTA1) and endogen-
ous DmpkmRNA levels were normalized to 18S rRNA expression.
Fluorescent in situ hybridization
Humanmyoblasts (5/5, 21/200 and 11/760) andmouse myoblasts
(DM500, Tg26, HSALR and WT) grown on gelatin-coated glass
cover slips were washed once with PBS and ﬁxed in 4% (w/v) for-
maldehyde, 2 m MgCl2 in PBS for 10 min at room temperature.
Cells were stored under 70% ethanol at 4°C. After two times PBS
wash, cells were pre-hybridized in 40% (v/v) deionized forma-
mide in 2× SSC for 20 min at room temperature, followed by over-
night hybridization with a 0.1 ng/μl Cy3-(CAG)7 probe (2′-O-
methyl phosphorothioate-modiﬁed) in 40% deionized formamide,
10% (w/v) dextran sulfate, 0.1% Triton X-100, 1 mg/ml herring
sperm DNA, 100 μg/ml yeast tRNA, 0.2% (w/v) BSA, 2 m VRC, 2×
SSC in a humidiﬁed chamber at 37°C. After two times PBS wash,
cells were counterstained with 0.33 μg/ml DAPI in PBS for 10 min
at room temperature, followed by a PBS wash, dehydration in
methanol and mounting in Mowiol. Images were acquired using
the Zeiss Axiophot2 Fluorescence microscope or Olympus IX-71
wide ﬁeld ﬂuorescence microscope.
RNA-sequencing
RNA-sequencing data fromhealthyandDM1-affected human tis-
sue samples [tibialis anterior (TA), quadriceps and heart] were
obtained from www.dmseq.org. RNA-sequencing signals of full-
length DMPK and GAPDH were used as an independent measure
for transcript abundance.
Statistical analysis
Endogenous and transgenic mRNA levels were compared be-
tween time points and models, using a one-way analysis of vari-
ance (ANOVA) test, followed by a post-test for linear trend or
Tukey’s multiple comparison test. All values in graphs are pre-
sented asmean±SEM. Foci countswere compared between differ-
ent myoblast lines with a one-way ANOVA test and Tukey’s
multiple comparisons post-test. Data are visualized as scatter
plot, each dot representing one observation, and the mean is
shown. Statistical analyses were performed with GraphPad
Prism version 5.01 for Windows.
Supplementary Material
Supplementary Material is available at HMG online.
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